ACTG, AIDS Clinical Trials Research Group - A5289 and A5255

Investigator: Anne Luetkemeyer, MD
Sponsor: Brigham and Women's Hospital

Location(s): United States


The AIDS Clinical Trials Group (ACTG) was initially established in 1987 to broaden the scope of the AIDS research effort of the National Institute of Allergy and Infectious Diseases (NIAID). The ACTG established and supports the largest Network of expert clinical and translational investigators and therapeutic clinical trials units in the world, including sites in resource-limited countries. These investigators and units serve as the major resource for HIV/AIDS research, treatment, care, and training/education in their communities.

The mission of the ACTG is to develop and conduct scientifically rigorous translational research and therapeutic clinical trials in the U.S. and internationally that

  1. Investigate the viral and immune pathogenesis of HIV-1 infection and its complications;
  2. Evaluate novel therapeutic agents and the most effective approaches and strategies for the use of existing agents to treat HIV-1 infection;
  3. Evaluate interventions and strategies to treat and prevent HIV-related opportunistic infections, co-infections, complications of therapies, and other HIV-1-related co-morbidities;
  4. Publish and disseminate the findings from these studies to improve clinical care, prevent or delay HIV disease progression, and reduce or eliminate the morbidity and mortality associated with HIV-1 infection and its associated complications.

5289-TMC-207 substitution of standard drugs for TB treatment: Disease caused by Mycobacterium tuberculosis continues as a global epidemic: over 2 billion people harbor latent TB infection, and more than 9 million new TB cases, of whom 500,000 are multidrug-resistant (MDR), and nearly 2 million deaths are estimated to occur each year. New drugs are required to shorten treatment duration of drug-sensitive TB and for the treatment of MDR-TB. TMC207 is a first-in-class diarylquinoline compound with a novel mechanism of action, the inhibition of bacterial ATP synthase, and potent activity against drug-sensitive and drug-resistant TB. It has bactericidal and sterilizing activity against M. tuberculosis and other mycobacterial species, but little activity against other bacteria.

A5525 - FASTER: Rapid TB DST study : Rapid Tuberculosis drug susceptibility testing study